American biotechnology firm Novavax said at this time that the COVID-19 vaccine it’s growing has proven to have 90.4% effectiveness in a Part 3 scientific trial carried out in the USA and Mexico. The outcomes of the trial, which included 29,960 contributors, yielded an efficacy on par with that of vaccines from Pfizer-BioNTech and Moderna. It was additionally proven to ...